Privium Fund Management B.V. Purchases 1,810 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Privium Fund Management B.V. increased its stake in Krystal Biotech, Inc. by 24.1% during the 2nd quarter, owning a total of 9,320 shares valued at approximately $1,296,000.
• Shares of Krystal Biotech, Inc. recently traded at $195.96 with a market capitalization of $5.67 billion, and have a 12-month trading range between $122.80 and $207.84.
• The company reported earnings of $1.29 per share for the latest quarter, surpassing analyst expectations of $1.08, with a revenue of $96.04 million.

Privium Fund Management B.V. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,320 shares of the company's stock after buying an additional 1,810 shares during the period. Krystal Biotech comprises approximately 0.3% of Privium Fund Management B.V.'s investment portfolio, making the stock its 28th biggest position. Privium Fund Management B.V.'s holdings in Krystal Biotech were worth $1,296,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brooklyn Investment Group grew its position in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after acquiring an additional 105 shares during the last quarter. Twin Tree Management LP purchased a new stake in shares of Krystal Biotech during the first quarter valued at $29,000. Smartleaf Asset Management LLC grew its holdings in shares of Krystal Biotech by 128.3% in the first quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after purchasing an additional 177 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Krystal Biotech in the 1st quarter worth about $74,000. Finally, GAMMA Investing LLC increased its stake in Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Trading Up 3.0%

Shares of NASDAQ:KRYS opened at $195.96 on Tuesday. The company has a market capitalization of $5.67 billion, a PE ratio of 39.83 and a beta of 0.64. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The business's fifty day simple moving average is $161.87 and its 200-day simple moving average is $151.27.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The company had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a "buy" rating in a report on Friday. HC Wainwright restated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Monday, September 15th. Chardan Capital lowered their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Finally, Citigroup reissued a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $223.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.